Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ireland Natalizumab (TYSABRI®) Observational Program (iTOP)

NCT01943526 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01943526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01943526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ireland Natalizumab (TYSABRI®) Observational Program (iTOP)
Lead sponsor
Biogen
Phase
Observational
Overall status
Completed
Start date
November 30, 2011
Completion date
December 31, 2017
Enrollment
191 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis